Zetaglim-M1 Tablet PR is a combination oral antihyperglycemic agent containing Glimepiride 1mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, enhances pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to improved glycemic control. The prolonged-release formulation of Zetaglim-M1 ensures a sustained therapeutic effect, promoting better patient compliance and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. This combination therapy is particularly beneficial for patients inadequately controlled on diet and exercise alone or those requiring dual pharmacologic intervention to achieve target glycemic levels. Zetaglim-M1 should be used as part of a comprehensive diabetes management plan, including diet modification and regular physical activity. It is contraindicated in patients with severe renal impairment, metabolic acidosis, or known hypersensitivity to either component. Regular monitoring of blood glucose, renal function, and potential adverse effects is essential during therapy. Dose adjustments may be necessary based on clinical response and tolerability. Zetaglim-M1 Tablet PR offers an effective option for optimizing glycemic control in type 2 diabetes mellitus.